Prostate cancer diagnostics with 68Ga-PSMA

Diagnostics of Prostate Cancer

„MedVision” offers progressive prostate cancer diagnostics with 68Ga-PSMA, that allows to effectively discover metastatic prostate cancer and bone metastases, as well as to detect the relapsed prostate cancer location and stage.

PSMA PET/CT examination is especially crucial for those 15-20% of all prostate cancer patients whose disease relapses after previous surgery or radiation therapy - it provides precise and early diagnosis of recurrence and it is extremely important for patient counselling and treatment selection.

  • PET Imaging with 68Ga-PSMA ligand can present lesions suspicious for prostate cancer with excellent contrast and a high detection rate even when the level of prostate specific antigen is low (PSA below 1 ng/mL).

  • PET/CT PSMA is able to identify fast-growing, aggressive tumors. In addition, it may be used in place of a bone scan to painlessly determine whether prostate cancer has spread to the bone.

  • PET/CT PSMA is able to determine the extent of prostate cancer and whether it has spread to the lymph nodes or other parts of the body, unlike traditional imaging technologies such as magnetic resonance imaging (MRI) and computed tomography (CT), which are often unable to detect the spread of prostate cancer cells.

  • PET/CT PSMA helps physicians select the most effective therapy for prostate cancer, taking into account a tumor’s unique molecular properties and whether the cancer is localized or diffuse, or spread out.

  • PET-CT has proven very effective in helping physicians monitor patient response to treatment of advanced-stage prostate cancer.

  • PSMA specifically marks prostate cancer cells and it becomes possible to differentiate the inflammatory processes from cancer.
  • With a single PET/CT examination it is possible to determine the existance of the metastases in soft tissues and in bones with a higher accuracy as compared to other diagnostic methods – computed tomography, magnetic resonance imaging and scintigraphy.
  • What is PSMA?
    PSMA is prostate-specific membrane antigen, which is overexpressed on the surface of prostate cancer cells and can be detected even after the disease has become metastatic.

    What is 68Ga?
    68Ga is a positron-emitting radioisotope, which is combined with the PSMA (collectively known as 68Ga-PSMA) and injected prior to PET/CT scanning. Once administered, the agent binds to cells expressing PSMA and emits a signal detected by the PET scanner.

    After applying for a consultation, you can get your PET/CT examination as soon as your arrival documentation (visa, flight ticket etc.) is ready.

    Our staff will help you to book a hotel, meet you upon arrival, explain how to get to our medical centre and how to prepare for the examination.

    PET/CT has been proven to exhibit high diagnostic accuracy and is increasingly established as the primary staging tool in prostate cancer and in patients with suspicious recurrent disease.